Stefan Bernstein explains how the EU/Greenland critical raw materials partnership benefits GreenRoc. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE
Stefan Bernstein explains how the EU/Greenland critical raw materials partnership benefits GreenRoc
Stefan Bernstein explains how the EU/Greenland critical raw materials partnership benefits GreenRocView Video
Utilico Insights - Jacqueline Broers assesses why Vietnam could be the darling of Asia for investors
Utilico Insights - Jacqueline Broers assesses why Vietnam could be the darling of Asia for investorsView Video

Latest Share Chat

ValiRx CEO confirms the TheoremRx deal remains 'on track' with payments expected before year-end


London South East were joined at their final live event of the year by Suzanne Dilly, CEO at AIM-listed ValiRX (VAL), the cancer and women's health drug developer which is also hoping to be become a service company or CRO to the pharmaceutical industry, generating additional revenue streams for the business.

What ValiRX does is take very early stage discoveries from universities or health charities and take these therapeutic development programmes in the fields of oncology or womens health and make them clinic-ready and partnership-ready.

A letter of intent to licence Val201 was signed in early November 2021 with TheoremRx Inc, a SPV, special purpose vehicle. briefly, VAL201 is a short peptide being studied as a potential treatment for prostate cancer. The potential value of the deal would be in excess of $61 million dollars US plus royalties for the first cancer indication, with 37.5M for each later indication.

Suzy confirmed that she thought this deal would be signed and become binding by the year-end or soon after, and the revenue streams generated by the deal would finance the new strategy. The new strategy involves data, which is key to clinical breakthroughs. Data generated from the ValiRx labs could better focus their drug development pipeline and be used on behalf of others.

Four CEO's present on London South East 8.11.2022: ValiRx, Poolbeg Pharma, enCore Energy, Goldplat

Suzy Dilly, ValiRx CEO reiterates her support for TheoremRx and hails 'brilliant science' Cytolytix

What's Hot from Sept. 21st #MONY #TEK #IAG #WTB #VAL

Related Shares

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.